Therapeutic potential of drugs targeting pathophysiology of intracerebral hemorrhage: From animal models to clinical applications

Kuo Hsing Liao, Chih Wei Sung, Ya Ni Huang, Wei Jiun Li, Po Chuan Yu, Jia Yi Wang

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Intracerebral hemorrhage (ICH) is one of the most common forms of cerebral hemorrhage, the morbidity and death of ICH is high worldwide. ICH can be spontaneous or caused by hypertension, coagulopathy, angiopathy, head trauma, bleeding disorders, tumors, or drug usage. ICH is the most serious and least treatable form of hemorrhagic stroke, with rapidly increasing hematoma size and often resulting in significant brain injury and long term neurological deficits. Surgical hematoma evacuation remains controversial. The currently therapy is mainly supportive with limited benefit. New therapeutic approaches are desperately needed. Methods: In this review, we provide an overview of the published literature concerning the pathophysiology leading to the ongoing neurologic damage, Emerging information of the physio-pathologic mechanisms of injury that occur after ICH is available from current animal models. Ideal therapeutic strategies should target on the pathophysiology of ICH. This review summarizes the recent advances in developing pharmaceutical agents in terms of therapeutic targets and effects in pre-clinical and clinical studies. Results: Recent animal and clinical studies have provided important information about the parallel and sequential deleterious mechanisms underlying ICH-induced brain injury and pharmacological agents targeting on these mechanisms. Neuroscientists have paid more attention to novel drug development that target on antioxidants, antiinflammatory, and anti-apoptosis for neuroprotection after ICH. Conclusion: Although ICH remains without an approved treatment proven to decrease morbidity and mortality, notable advances in the understanding of ICH pathophysiology and new drug development have been made in the last decade.

Original languageEnglish
Pages (from-to)2212-2225
Number of pages14
JournalCurrent Pharmaceutical Design
Volume23
Issue number15
DOIs
Publication statusPublished - 2017

Fingerprint

Cerebral Hemorrhage
Drug Delivery Systems
Animal Models
Therapeutics
Hematoma
Pharmaceutical Preparations
Brain Injuries
Morbidity
Therapeutic Uses
Craniocerebral Trauma
Nervous System
Anti-Inflammatory Agents
Antioxidants
Stroke
Pharmacology
Apoptosis
Hemorrhage
Hypertension

Keywords

  • Anti-inflammation
  • Antioxidant
  • ICH
  • Neurological deficits
  • Neuroprotection
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Therapeutic potential of drugs targeting pathophysiology of intracerebral hemorrhage : From animal models to clinical applications. / Liao, Kuo Hsing; Sung, Chih Wei; Huang, Ya Ni; Li, Wei Jiun; Yu, Po Chuan; Wang, Jia Yi.

In: Current Pharmaceutical Design, Vol. 23, No. 15, 2017, p. 2212-2225.

Research output: Contribution to journalReview article

@article{1d75b763509e461bb2330e9801682f3d,
title = "Therapeutic potential of drugs targeting pathophysiology of intracerebral hemorrhage: From animal models to clinical applications",
abstract = "Background: Intracerebral hemorrhage (ICH) is one of the most common forms of cerebral hemorrhage, the morbidity and death of ICH is high worldwide. ICH can be spontaneous or caused by hypertension, coagulopathy, angiopathy, head trauma, bleeding disorders, tumors, or drug usage. ICH is the most serious and least treatable form of hemorrhagic stroke, with rapidly increasing hematoma size and often resulting in significant brain injury and long term neurological deficits. Surgical hematoma evacuation remains controversial. The currently therapy is mainly supportive with limited benefit. New therapeutic approaches are desperately needed. Methods: In this review, we provide an overview of the published literature concerning the pathophysiology leading to the ongoing neurologic damage, Emerging information of the physio-pathologic mechanisms of injury that occur after ICH is available from current animal models. Ideal therapeutic strategies should target on the pathophysiology of ICH. This review summarizes the recent advances in developing pharmaceutical agents in terms of therapeutic targets and effects in pre-clinical and clinical studies. Results: Recent animal and clinical studies have provided important information about the parallel and sequential deleterious mechanisms underlying ICH-induced brain injury and pharmacological agents targeting on these mechanisms. Neuroscientists have paid more attention to novel drug development that target on antioxidants, antiinflammatory, and anti-apoptosis for neuroprotection after ICH. Conclusion: Although ICH remains without an approved treatment proven to decrease morbidity and mortality, notable advances in the understanding of ICH pathophysiology and new drug development have been made in the last decade.",
keywords = "Anti-inflammation, Antioxidant, ICH, Neurological deficits, Neuroprotection, Therapeutics",
author = "Liao, {Kuo Hsing} and Sung, {Chih Wei} and Huang, {Ya Ni} and Li, {Wei Jiun} and Yu, {Po Chuan} and Wang, {Jia Yi}",
year = "2017",
doi = "10.2174/1381612822666161027151624",
language = "English",
volume = "23",
pages = "2212--2225",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Therapeutic potential of drugs targeting pathophysiology of intracerebral hemorrhage

T2 - From animal models to clinical applications

AU - Liao, Kuo Hsing

AU - Sung, Chih Wei

AU - Huang, Ya Ni

AU - Li, Wei Jiun

AU - Yu, Po Chuan

AU - Wang, Jia Yi

PY - 2017

Y1 - 2017

N2 - Background: Intracerebral hemorrhage (ICH) is one of the most common forms of cerebral hemorrhage, the morbidity and death of ICH is high worldwide. ICH can be spontaneous or caused by hypertension, coagulopathy, angiopathy, head trauma, bleeding disorders, tumors, or drug usage. ICH is the most serious and least treatable form of hemorrhagic stroke, with rapidly increasing hematoma size and often resulting in significant brain injury and long term neurological deficits. Surgical hematoma evacuation remains controversial. The currently therapy is mainly supportive with limited benefit. New therapeutic approaches are desperately needed. Methods: In this review, we provide an overview of the published literature concerning the pathophysiology leading to the ongoing neurologic damage, Emerging information of the physio-pathologic mechanisms of injury that occur after ICH is available from current animal models. Ideal therapeutic strategies should target on the pathophysiology of ICH. This review summarizes the recent advances in developing pharmaceutical agents in terms of therapeutic targets and effects in pre-clinical and clinical studies. Results: Recent animal and clinical studies have provided important information about the parallel and sequential deleterious mechanisms underlying ICH-induced brain injury and pharmacological agents targeting on these mechanisms. Neuroscientists have paid more attention to novel drug development that target on antioxidants, antiinflammatory, and anti-apoptosis for neuroprotection after ICH. Conclusion: Although ICH remains without an approved treatment proven to decrease morbidity and mortality, notable advances in the understanding of ICH pathophysiology and new drug development have been made in the last decade.

AB - Background: Intracerebral hemorrhage (ICH) is one of the most common forms of cerebral hemorrhage, the morbidity and death of ICH is high worldwide. ICH can be spontaneous or caused by hypertension, coagulopathy, angiopathy, head trauma, bleeding disorders, tumors, or drug usage. ICH is the most serious and least treatable form of hemorrhagic stroke, with rapidly increasing hematoma size and often resulting in significant brain injury and long term neurological deficits. Surgical hematoma evacuation remains controversial. The currently therapy is mainly supportive with limited benefit. New therapeutic approaches are desperately needed. Methods: In this review, we provide an overview of the published literature concerning the pathophysiology leading to the ongoing neurologic damage, Emerging information of the physio-pathologic mechanisms of injury that occur after ICH is available from current animal models. Ideal therapeutic strategies should target on the pathophysiology of ICH. This review summarizes the recent advances in developing pharmaceutical agents in terms of therapeutic targets and effects in pre-clinical and clinical studies. Results: Recent animal and clinical studies have provided important information about the parallel and sequential deleterious mechanisms underlying ICH-induced brain injury and pharmacological agents targeting on these mechanisms. Neuroscientists have paid more attention to novel drug development that target on antioxidants, antiinflammatory, and anti-apoptosis for neuroprotection after ICH. Conclusion: Although ICH remains without an approved treatment proven to decrease morbidity and mortality, notable advances in the understanding of ICH pathophysiology and new drug development have been made in the last decade.

KW - Anti-inflammation

KW - Antioxidant

KW - ICH

KW - Neurological deficits

KW - Neuroprotection

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85025144841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025144841&partnerID=8YFLogxK

U2 - 10.2174/1381612822666161027151624

DO - 10.2174/1381612822666161027151624

M3 - Review article

AN - SCOPUS:85025144841

VL - 23

SP - 2212

EP - 2225

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 15

ER -